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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a prevalent pathogen of
necrotizing fasciitis (NF) in Taiwan. A four-year NF cases and clinical and genetic differences between hospital
acquired (HA)- and community-acquired (CA)-MRSA infection and isolates were investigated.
Methods: A retrospective study of 247 NF cases in 2004-2008 and antimicrobial susceptibilities, staphylococcal
chromosomal cassette mec (SCCmec) types, pulsed field gel electrophoresis (PFGE) patterns, virulence factors, and
multilocus sequence typing (MLST) of 16 NF-associated MRSA in 2008 were also evaluated.
Results: In 247 cases, 42 microbial species were identified. S. aureus was the major prevalent pathogen and MRSA
accounted for 19.8% of NF cases. Most patients had many coexisting medical conditions, including diabetes
mellitus, followed by hypertension, chronic azotemia and chronic hepatic disease in order of decreasing
prevalence. Patients with MRSA infection tended to have more severe clinical outcomes in terms of amputation
rate (p < 0.05) and reconstruction rate (p = 0.001) than those with methicillin-sensitive S. aureus or non-S. aureus
infection. NF patients infected by HA-MRSA had a significantly higher amputation rate, comorbidity, C-reactive
protein level, and involvement of lower extremity than those infected by CA-MRSA. In addition to over 90% of
MRSA resistant to erythromycin and clindamycin, HA-MRSA was more resistant than CA-MRSA to trimethoprim-
sulfamethoxazole (45.8% vs. 4%). ST59/pulsotype C/SCCmec IV and ST239/pulsotype A/SCCmec III isolates were the
most prevalent CA- and HA-MRSA, respectively in 16 isolates obtained in 2008. In contrast to the gene for
g-hemolysin found in all MRSA, the gene for Panton-Valentine leukocidin was only identified in ST59 MRSA isolates.
Other three virulence factors TSST-1, ETA, and ETB were occasionally identified in MRSA isolates tested.
Conclusion: NF patients with MRSA infection, especially HA-MRSA infection, had more severe clinical outcomes
than those infected by other microbial. The prevalent NF-associated MRSA clones in Taiwan differed distinctly from
the most predominant NF-associated USA300 CA-MRSA clone in the USA. Initial empiric antimicrobials with a
broad coverage for MRSA should be considered in the treatment of NF patients in an endemic area.
Background
Necrotizing fasciitis (NF) is a rare and life-threatening
infection that involves deep soft tissue and is characterized
by widespread fascial necrosis, with a mortality of 25.3-
73% [1-3]. Necrotizing fasciitis typically is polymicrobial
infection caused by aerobic and anaerobic organism that
participate in synergistic infection; whereas Group A
Streptococcus, Clostridium spp., Vibrio spp. and Klebsiella
spp. have been the cause of monomicrobial infection.
Although Staphylococcus aureus is the most prevalent
pathogen in both hospitals and communities and MRSA
has become a common isolate associated with skin and
soft tissue infections globally over the past few years,
monomicrobial MRSA necrotizing fasciitis has been
reported only in a few studies [4-6]. In Taiwan, MRSA
accounts for 53-83% of S. aureus isolates in most major
hospitals [7,8]. Community-acquired MRSA (CA-MRSA)
has become increasingly endemic, accounting for 74% and
28% of all MRSA in two studies that were performed in
* Correspondence: cschu@mail.ncyu.edu.tw
1Department of Microbiology, Immunology, and Biopharmaceuticals,
National Chiayi University, No 300, University Road, Chiayi, 60004, Taiwan,
ROC
Full list of author information is available at the end of the article
Changchien et al. BMC Infectious Diseases 2011, 11:297
http://www.biomedcentral.com/1471-2334/11/297
© 2011 Changchien et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.northern and central Taiwan, respectively [9]. Recently,
MRSA has been identified as an important cause of necro-
tizing fasciitis in Taiwan [10].
Several virulence factors are reportedly associated with
the pathogenicity of skin and soft tissue infections. Pan-
ton-Valentine leukocidin (PVL), a pore-forming exotoxin,
and g-hemolysin (Hlg) are associated with pus-forming
diseases. CA-MRSA isolates with the PVL genes generally
cause skin and soft tissue infections and necrotizing fascii-
tis [4,11]. Toxic shock syndrome toxin 1 (TSST-1) can
cause in part a desquamative skin rash and toxemic syn-
drome [12]. Exfoliatin A (ETA) and exfoliatin B (ETB) are
associated with numerous blistering skin diseases and sta-
phylococcal scalded-skin syndrome [13]. The variable clin-
ical presentations of S. aureus skin and soft tissue
infections are believed to be associated with the particular
combinations of virulence factors and regulatory genes
given an appropriate genetic background [14].
In staphylococcal species, low-affinity penicillin-binding
protein 2a, which is responsible for methicillin resistance,
is produced by the mecA gene in an exogenous mobile sta-
phylococcal chromosomal cassette mec (SCCmec) [15,16].
Hence a methicillin-susceptible S. aureus (MSSA) isolate
may acquire the SCCmec elements and thereby become an
MRSA isolate [17]. Based on variations in the ccr operon
and mec complexes of the SCCmec,a tl e a s ts e v e nS C C mec
types have been identified as having some clinical implica-
tions [18]. The SCCmec IV element (~24 kb) is most com-
monly identified in CA-MRSA isolates, whereas the
SCCmec II and III elements are often found in HA-MRSA
isolates [19,20].
The management of NF absolutely depends on the
prompt administering of suitable antibiotics and ade-
quate surgical debridement. Increasing prevalence of
MRSA, the choice of appropriate antibiotics for NF
patients in the community must now take into account
the increasing global prevalence of MRSA and the pat-
terns of antimicrobial susceptibility [21]. Therefore, a
study population of 247 NF cases in 2004-2008 and their
associated MRSA isolates were investigated to under-
stand the epidemiological or clinical effects of MRSA on
NF cases and clinical and genetic differences between
CA- and HA-MRSA. Further, antimicrobial susceptibility,
SCCmec types, pulsed field gel electrophoresis (PFGE)
patterns, virulence factors, and MLST types of MRSA
strains that were isolated from 16 NF patients in 2008
were examined.
Methods
Study population
A total of 247 NF patients were consecutively hospita-
lized and surgically treated at the 1000-bed Chiayi Chris-
tian Hospital in southern Taiwan from December 2004
to November 2008. A patient was included in the study if
the postoperative diagnosis in his or her surgical report
was of necrotizing fasciitis that this diagnosis was verified
by pathological examination, as determined by an elec-
tronic search and a discharge diagnosis of necrotizing
fasciitis. Necrotizing fasciitis is defined by the followings;
the presence of grayish necrotic fascia; a demonstrated
lack of resistance of muscular fascia that was freely dis-
sected using a blunt instrument along the normal adher-
ent tissue planes; the presence of foul-smelling “dish-
water” pus; and/or, extensive necrosis of the skin and
subcutaneous tissues [3]. Electronic and paper medical
records were reviewed for clinical variables that included
age, gender, infection site, and underlying chronic condi-
t i o n ss u c ha sd i a b e t e sm e l l i t us, hypertension, chronic
liver disease, coronary artery disease, chronic renal insuf-
ficiency, chronic obstructive pulmonary disease, and
malignancy. Empiric antibiotics that were used in initial
treatment, the number of surgical debridements and
reconstructions undergone, amputation, period of hospi-
talization, in-hospital mortality rate, laboratory findings
at the time of admission, and clinical outcomes in each
NF case were also evaluated. A surgeon and a nurse prac-
titioner of plastic surgery collected the data. These data
were then compared across four distinct groups with
different etiologic pathogens (non-S. aureus, MSSA, CA-
MRSA, and HA-MRSA) to determine whether the clini-
cal variables were associated in any way with MRSA
necrotizing fasciitis.
Antimicrobial susceptibility test
The susceptibility of S. aureus isolates to antimicrobials
clindamycin, erythromycin, fucidin, linezolid, oxacillin, tei-
coplanin, trimethoprim-sulfamethoxazole, and vancomycin
was performed by using disc diffusion and the guideline of
Clinical and Laboratory Standards Institute (CLSI) [22].
Isolates with zones of inhibition that fell into the category
of intermediate susceptibility to a given antibiotic were
regarded as susceptible isolates.
Characterization of NF-associated MRSA isolates
A total of 16 specimens were obtained from wound cul-
tures of NF patients upon initial surgical debridement
or from blood cultures of NF patients who had visited
hospital between January 2008 and November 2008.
Blood cultures were processed in a VITEK 2 GP system
(BioMerieux) in the hospital laboratory. Bacteria were
firstly analyzed by coagulase testing and Gram staining.
S. aureus was identified by the polymerase chain reaction
(PCR) amplification of S. aureus-specific clfA, 16S rDNA,
and nuc genes [23,24]. The S. aureus isolates BCRC
10781 and BCRC 15211 were used as methicillin-suscep-
tible and resistant reference strains, respectively. MRSA
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following definition. HA-MRSA is an MRSA isolate that
is obtained from patients who stay more than 48 hours
after admission to hospital, or who have established risk
factors, such as a history of HA-MRSA isolation, hospita-
lization, surgery, dialysis or admission to a nursing home,
skilled nursing facility or hospice in the past year or who
have a permanent indwelling catheter or medical device
that passes through the skin into the body [21]. In con-
trast, a CA-MRSA isolate is an MRSA isolate that is
obtained from a patient within 48 hours of admission
to the hospital and without the above conditions for
HA-MRSA.
Genetic analysis by pulsed field gel electrophoresis
(PFGE) and MLST
The genotype of each isolate was identified by SmaI-
digested PFGE analysis using a method described else-
where [25]. Briefly, whole-cell embedding agarose plugs
were digested using restriction endonuclease SmaI. The
DNA fragments were resolved using a CHEF DR-III appa-
ratus (Bio-Rad). The standard size marker was the MRSA
isolate BCRC 15211. Isolates are regarded as closely
related if they differ by no more than three fragments; as
possibly related if they differ by four to six fragments, and
unrelated if they differ by at least seven fragments [26].
MLST types of 16 CA- and HA-MRSA isolates were iden-
tified using the method that was described by Enright [27]
and by analysis of MLST databases (http://saureus.mlst.
net/).
PCR identification of SCCmec types and genes for
virulence factors PVL, Hlg, TSST-1, ETA, and ETB
SCCmec types I-IV were identified by multiplex PCR
amplification of SCCmec regions [16,28]. If not groupable
into types I-IV, isolates were grouped into SCCmec type V
or VT (or VII) by the PCR detection of ccrC (ccr5) homo-
logues [29-31]. Genes for virulence factors PVL, Hlg,
TSST-1, ETA, and ETB were identified by simplex and
multiplex PCR amplifications using primers described
elsewhere [14,32].
Statistical analysis
Categorical variables were presented as frequencies and
percentages, and continuous variables were presented as
means and standard deviations. The chi-square test or Fish-
er’s exact test were adopted to compare categorical data, as
appropriate. Continuous data were obtained by analysis of
variance to evaluate the differences between the groups,
and a post hoc comparison was conducted using the Tukey
honestly-significant difference test. All reported P values
were two-tailed, and a P value of 0.05 indicated statistical
significance. All analyses were performed using SPSS
software.
Results
Demographics and clinical variables
The dataset from the specified four-year period included
a total of 247 cases of necrotizing fasciitis, with a 19.8%
prevalence of MRSA as the causative organism of the
infection. The mean age, gender, mean number of sur-
geries and mortality rate of the NF patients did not vary
much with the cause of the infection by non-S. aureus,
MSSA, CA-MRSA, or HA-MRSA (Table 1). Most
patients in this investigation had multiple coexisting
medical conditions, including diabetes mellitus (62.8%),
hypertension (30.1%), chronic azotemia (28.2%) and
chronic hepatic disease (14.6%). The incidence of periph-
eral artery occlusive disease and malignancy was extre-
mely low in all four groups, which did not discernibly
differ in this respect. Patients who were infected by HA-
MRSA exhibited significantly more comorbidity and a
higher incidence of chronic azotemia than the other
three groups (p < 0.05). Regardless of infecting species,
the lower extremities were the most common infection
sites (p < 0.05). NF patients of two Vibrio monomicrobial,
three non-S. aureus polymicrobial, and one HA-MRSA
died. No death occurred in the MSSA and CA-MRSA
groups. Two CA-MRSA, one HA-MRSA, and four non-S.
aureus NF patients presented a systolic blood pressure of
<90 mm Hg when they arrived in the emergency room.
As determined by univariate analysis, patients who were
infected by CA-MRSA had a lower C-reactive protein
level than those infected by HA-MRSA, MSSA, or non-S.
aureus. Body temperature, leukocyte count and platelet
count at the time of admission to hospital were similar
among the four groups of NF patients. Patients who were
infected with MRSA tended to have more severe clinical
outcomes in terms of amputation rate (p < 0.05) and
reconstruction rate (p = 0.001) than those with MSSA or
non-S. aureus infection. Moreover, NF patients with HA-
MRSA infection had a higher rate of amputation on
admission (29.2%) than those with CA-MRSA infection
(8%) (p < 0.05).
Microbial associated with NF
From the initial wounds of the 247 NF patients or from
blood culture, 34 aerobic bacterial species, seven anaero-
bic bacterial species and one fungal species were identi-
fied (Table 2). The prevalence of polymicrobial and
monomicrobial infections was 55.5 and 44.5, respectively.
An average of 2.77 microbial species was identified in a
polymicrobial infection. The major bacterial species were
Staphylococcus spp., followed by Streptococcus spp.,
Enterococcus spp., Peptostrep spp., Bacteroides spp., Pre-
votella spp., Klebsiella spp., and E. coli. Generally, most
NF cases were polymicrobial infections. However, the
most monomicrobial infections for NF cases were caused
by Staphylococcus spp. (57.2%) and Vibrio spp. (9%). The
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increased gradually from 2006 to 2008, and MRSA was
the major pathogenic cause of necrotizing fasciitis in
2008 (Figure 1).
Management and antimicrobial susceptibility of 49 MRSA
infections
All patients were urgently treated with surgical debride-
ment or amputation of the infected part. Generally, the
wounds were repaired with delayed closure, split-thick-
ness skin grafts, or flap reconstructive surgery; the
remaining small skin defects were allowed to close by
secondary intention. Within 24 h after admission, most
patients with MRSA infections (41/49, 83.7%) were pre-
scribed empiric antibiotic therapy with b-lactam antimi-
crobials and gentamicin. No patient with MRSA
necrotizing fasciitis was prescribed empiric antibiotic
therapy with vancomycin. Vancomycin was subsequently
administered to 23 (46.9%) patients after the susceptibil-
ity test had been completed. All MRSA isolates were sus-
c e p t i b l et ol i n e z o l i d ,t e i c o p l a n i n ,a n dv a n c o m y c i n ,b u t
highly resistant to erythromycin and clindamycin (>90%)
and mildly resistant to tetracycline (>65%) and fucidin
(12%). Interestingly, resistance to trimethoprim-sulfa-
methoxazole differed significantly between CA- and HA-
MRSA groups (4% vs. 45.8%).
Table 1 Clinical characteristics of 247 NF cases and antimicrobial resistance of CA- and HA-MRSA isolates
Characteristic Non-S. aureus
(n = 156)
MSSA
(n = 42)
CA-MRSA
(n = 25)
HA-MRSA
(n = 24)
p-value
Age (mean, yr)
§
(years)
59.1 ± 13.0 56.0 ± 17.9 53.8 ± 14.3 57.4 ± 15.3 0.262
Male (n, %) 107 (68.6) 27 (64.3) 13 (52) 17 (70.8) 0.399
Comorbidities (n, %)
† 1.8 (1.2) 1.9 (1.5) 1.4 (1.1) 2.9 (1.5) <0.001***
Hospitalization (mean, day)
§ 17.2 ± 10.6 15 ± 8.6 13.2 ± 8.3 20.3 ± 8.1 0.052
Underlying chronic disease
Diabetes mellitus (n, %) 95 (60.9) 25 (59.5) 15 (60.0) 20 (83.3) 0.183
Hypertension (n, %) 59 (37.8) 17 (40.5) 7 (28.0) 11 (45.8) 0.616
Chronic hepatic disease (n, %) 19 (12.2) 8 (19) 4 (16) 5 (20.8) 0.451
Malignancy (n, %) 6 (3.8) 2 (4.8) 0 (0) 0 (0) 0.765
Obesity (n, %) 17 (10.9) 3 (7.1) 0 (0) 1 (4.2) 0.300
Pulmonary disease (n, %) 11 (7.1) 3 (7.1) 0 (0) 2 (8.3) 0.600
Chronic azotemia (n, %) 26 (16.7) 6 (14.3) 2 (8) 10 (41.7) 0.019*
Operative procedure (mean, n) 2.1 ± 1.1 1.9 ± 0.6 2.1 ± 0.9 2.4 ± 1.5 0.237
Reconstructive surgery (n, %) 15 (9.6) 2 (4.8) 8 (32) 7 (29.2) <0.001***
Amputation (n, %) 18 (11.5) 2 (4.8) 2 (8) 7 (29.2) 0.037*
Mortality (n, %) 5 (3.2) 0 (0) 0 (0) 1 (4.2) 0.542
Site of infection
Upper extremity (n, %) 18 (11.5) 8 (19) 4 (16) 1 (4.2) 0.315
Lower extremity (n, %) 103 (66) 25 (59.5) 17 (68) 20 (83.3) 0.005**
Head and neck (n, %) 1 (0.6) 4 (9.5) 2 (8) 1 (4.2) 0.014*
Trunk (n, %) 34 (21.8) 5 (11.9) 2 (8) 2 (8.3) 0.118
Body temperature (°C) (mean)
§ 36.9 ± 0.8 36.9 ± 0.5 36.8 ± 0.5 37.1 ± 0.7 0.624
Shock (n, %) 4 (2.6) 0 (0) 2 (8) 1 (4.2) 0.170
Leukocyte count (mean cells/mm
3)
§ 13.9 ± 7.4 14.1 ± 5.1 12.9 ± 5.5 15.1 ± 7.7 0.752
Platelet count (mean, per mm
3) 248.3 ± 107.9 263.2 ± 96.9 290.5 ± 120.2 293.9 ± 99.5 0.101
C-reactive protein (mean, mg/dl)
‡ 15.8 ± 13.2 12.2 ± 11.8 10.4 ± 10.6 25.5 ± 14.8 0.005**
Antimicrobials resistance CA-MRSA HA-MRSA
Clindamycin (n, %) 23 (92.0) 23 (95.8) 0.576
Erythromycin (n, %) 23 (92.0) 23 (95.8) 0.576
Fucidic acid (n, %) 3 (12.0) 3 (12.5) 0.957
Trimethoprim-sulfamethoxazole (n, %) 1 (4.0) 11 (45.8) <0.001***
§ Data represents as mean ± standard deviation or number of cases (prevalence, %).
† Post hot comparison using Tukey mothod: Non-S. aureus < HA-MRSA, p = 0.001; MSSA < HA-MRSA, p = 0.02; CA-MRSA < HA-MRSA, p < 0.001.
‡ Post hot comparison using Tukey mothod: Non-S. aureus < HA-MRSA, p = 0.045; MSSA < HA-MRSA, p = 0.008; CA-MRSA < HA-MRSA, p = 0.007.
* indicates significant differences among four groups (p < 0.05); ** and *** indicates highly significant among four groups with p < 0.01 and p < 0.001
respectively.
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Organism Monomicrobial Polymicrobial Total (%)
Number A,% B,% Number A,% B,%
Aerobic
Gram-positive
Staphylococcus aureus
MRSA 34 30.9 13.8 15 3.9 6.1 49 (19.8)
MSSA 26 23.6 10.5 16 4.2 6.5 42 (16.6)
Coagulase-negative Staphylococcus 3 2.7 1.2 13 3.4 5.3 16 (6.5)
Staphylococcus saprophyticus 1 0.3 0.4 1 (0.4)
Streptococcus viridans 1 0.9 0.4 18 4.7 7.3 19 (7.7)
Streptococcus
Group A Streptococcus 6 5.5 2.4 9 2.4 3.6 15 (6.1)
Group B Streptococcus 3 2.7 1.2 14 3.7 5.7 17 (6.9)
Group G Streptococcus 6 1.6 2.4 6 (2.4)
Other Streptococcus 1 0.3 0.4 1 (0.4)
Enterococcus 4 3.6 1.6 33 8.7 13.4 37 (15.0)
Bacillus spp. 4 1.1 1.6 4 (1.6)
Corynebacterium spp. 2 0.5 0.8 2 (0.8)
Gram-negative
Vibrio spp. 10 9.1 4.0 4 1.1 1.6 14 (5.7)
Klebsiella spp. 6 5.5 2.4 26 6.8 10.5 32 (13.0)
Proteus spp. 3 2.7 1.2 21 5.5 8.5 24 (9.7)
Escherichia coli 2 1.8 0.8 23 6.1 9.3 25 (10.1)
Morganella morganii 1 0.9 0.4 15 3.9 6.1 16 (6.5)
Enterobacter spp. 1 0.9 0.4 12 3.2 4.9 13 (5.3)
Serratia marcescens 1 0.9 0.4 2 0.5 0.8 3 (1.2)
Shewanella puterfacines 1 0.9 0.4 1 0.3 0.4 2 (0.8)
Pseudmonas aeruginosa 9 2.4 3.6 9 (3.6)
Aeromonas spp. 7 1.8 2.8 7 (2.8)
Citrobacter spp. 4 1.1 1.6 4 (1.6)
Acinetobacter baumannii 3 0.8 1.2 3 (1.2)
Stenotroph maltophilia 2 0.5 0.8 2 (0.8)
Burkholderia gladioli 1 0.3 0.4 1 (0.4)
Haemophilus influenzae 1 0.3 0.4 1 (0.4)
Providencia rettger 1 0.3 0.4 1 (0.4)
Anaerobic
Bacteroides spp. 3 2.7 1.2 29 7.6 11.7 32 (13.0)
Peptostrept spp. 2 1.8 0.8 35 9.2 14.2 37 (15.0)
Prevotella spp. 1 0.9 0.4 31 8.2 12.6 32 (13.0)
Fusobacterium spp. 1 0.9 0.4 9 2.4 3.6 10 (4.0)
Veillonella spp. 8 2.1 3.2 8 (3.2)
Clostridium spp. 2 0.5 0.8 2 (0.8)
Porphyromonas spp. 1 0.3 0.4 1 (0.4)
Fungus
Candida albicans 1 0.9 0.4 1 0.3 0.4 2 (0.8)
Total 110 100 44.5 380 100 55.5 247 (100)
*:A = [Number of isolate of the microbial species/Total number of monomicrobial (110) or polymicrobial (380)] × 100%
B = (Number of isolation/247) × 100%
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TSST-1, ETA, and ETB
PCR amplification identified five SCCmec types, which
were SCCmec III, IV, V, VT (or VII) and the nontypeable
type. The most prevalent SCCmec types were SCCmec IV
in CA-MRSA and SCCmec III in HA-MRSA. Isolates
that contained the SCCmec III element were multi-drug
resistant to b-lactams, erythromycin, clindamycin, and
trimethoprim-sulfamethoxa z o l e .U n l i k eas i n g l eH A -
MRSA isolate that contained the pulsotype C/SCCmec IV
element, isolates that contained SCCmec I V ,V ,o rV I I
elements were susceptible to trimethoprim-sulfamethox-
azole; however, all isolates were resistant to b-lactams,
erythromycin, and clindamycin. Among the genes for five
virulence factors, those for Hlg were present in all iso-
lates and those for ETA, TSST-1, and PVL were present
in a few isolates. Notably, the PVL genes were identified
in two CA-MRSA isolates and one HA-MRSA isolate.
The ETB gene was not detected in any sample (Table 3).
PFGE patterns and MLST types
Analysis of SmaI-digested PFGE identified 16 MRSA iso-
lates associated with seven pulsotypes (Figure 2). In com-
parison with the resolutions of PFGE patterns described
by Huang [7], genotype A, C, and D, the major clones in
that report, consisted of 81.3% of the isolates in the pre-
sent study (Table 3). The pulsotypes were associated with
the SCCmec types as pulsotype A/SCCmec III and pulso-
type C/SCCmec I V .I nt h ep u l s o t y p eD ,S C C mec types
IV, V, and VII were identified and three out of four pul-
sotype D isolates had the genes for PVL. MLST analysis
identified six MLST types in that 75% (12/16) of the iso-
lates were ST59 and ST 239. Additionally, other four
types were ST9, ST30, ST1279-like, ST238- and 585-like
types (Table 3).
Discussion
The mainstay treatments of necrotizing fasciitis are urgent
operation for decompression and drainage, subsequently
repeated debridement, and appropriate antibiotics. The
selection of appropriate antimicrobial agents for any sus-
pected necrotizing fasciitis must take into account the nat-
ure of patient’s exposure and local epidemiologic data.
However, there are no reliable epidemiological or clinical
risk factors that could distinguish patients infected with
MRSA from those infected with MSSA or non-S. aureus
[33]. With the explosion of MRSA infections, recent
reports have established that MRSA is responsible for 3.6%
to 39% of NF disease [1,4-6]. In this study, the prevalence
of MRSA in 247 NF cases over a four-year period was
19.8% (Table 1 and Figure 1). The variation in the preva-
lence of MRSA necrotizing fasciitis around the world may
reflect variations in genetic background and local epide-
miology. MRSA is gradually becoming the main monomi-
crobial pathogen to cause NF in Taiwan, reflecting changes
in the microbial flora in this area. In this investigation, the
observed mortality rate did not significantly vary among
the four groups, even though NF patients with HA-MRSA
infection had a higher incidence of comorbidity on admis-
sion than those infected by CA-MRSA, MSSA or non-S.
aureus group. However, the amputation rate and recon-
struction rate for NF patients with MRSA infection were
18.4% and 30.6% respectively - significantly higher than
those infected by non-S. aureus. These analytical findings
further highlight the role of MRSA as an important patho-
gen in causing a destructive and deep-seated infection.
Recent reports have demonstrated that the CA-MRSA
strains with specific virulence factors have a shorter dou-
bling time than HA-MRSA strains and tend to be more
virulent [34]. PVL has been associated with epidemic
CA-MRSA strains causing lethal necrotizing fasciitis [35].
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Figure 1 Prevalence of MRSA and MSSA associated with 247 NF cases in 2005 to 2008.
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Isolate ST Allelic profile PFGE Pulsotype* Antibiogram SCCmec CA/HA Virulence Clinical
arcC aroE glpF gmk pta tpi yqiL genotype CC CIP ERY FA GM KM SXT TE type MRSA factor association
SA141 9 3 3 1 1 1 1 10 gt-7 ND1 R R R S R R S R V HA Hlg Healed
SA93 30 2 2 2 2 6 3 2 gt-8 ND2 R I R S R R S S IV CA Hlg Bacteremia
SA49 59 19 23 15 2 19 20 15 gt-2a C R I R S R R S S IV HA Hlg, ETA Amputation
SA52 59 19 23 15 2 19 20 15 gt-2b C R I R S R R S R IV CA Hlg, TSST Healed
SA104 59 19 23 15 2 19 20 15 gt-2c C R I R S I I S S IV HA Hlg Healed
SA46 59 19 23 15 2 19 20 15 gt-2d C R I R S I R S S IV CA Hlg, ETA Amputation
SA10 59 19 23 15 2 19 20 15 gt-2e C R I R S I R S R IV HA Hlg Healed
SA215 59 19 23 15 2 19 20 15 gt-3 D R I R S I R S S V HA Hlg, PVL Skin graft
SA100 59 19 23 15 2 19 20 15 gt-4 D R I R S I R R R IV HA Hlg Bacteremia,
Amputation
SA123 59 19 23 15 2 19 20 15 gt-5a D R I R S I R S R VII CA Hlg, PVL Healed
SA156 59 19 23 15 2 19 20 15 gt-5b D R I R S I R S S V CA Hlg, PVL Skin graft
SA19 239 2 3 1 1 4 4 3 gt-1a A R R R R R R R R III HA Hlg Amputation
SA31 239 2 3 1 1 4 4 3 gt-1b A R R R S R R R R III HA Hlg Bacteremia
SA151 239 2 3 1 1 4 4 3 gt-1c A R R R S R R S R III HA Hlg Amputation
SA167 238 &
585 like
2 1a 1 1 4 4 1b gt-1c A R R R S R R S R III HA Hlg Bacteremia, amputation
SA165 1279 like 1 3c 1 1 12 1 3 gt-6 O R I R S R R S R Non-type HA Hlg Bacteremia
* ND means that pulsotype could not be determined and pulsotypes were similar to those reported in Huang et al. [7].
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1Contrary to these findings, in the present investigation,
all of the patients who were infected by CA-MRSA sur-
vived. Miller [4] reported no deaths in their series,
hypothesizing that necrotizing fasciitis that is caused by
CA-MRSA may be less virulent than similar infections
that are caused by other organisms. According to the
findings herein, patients who were infected by CA-MRSA
tended to have less severe clinical characteristics in terms
of comorbidity, amputation rate and the involvement of
lower extremities than those with HA-MRSA infections,
suggesting that it may be associated with limited eleva-
tion of C-reactive protein in patients as well as lower
virulence of CA-MRSA strains which differed distinctly
from the highly virulent PVL-positive CA-MRSA strains
spreading elsewhere.
I nt h ep r e s e n ts t u d y ,t h eP V Lg e n e sw e r eo n l yi d e n t i -
fied in two CA- and one HA-MRSA isolates. Genes for
the virulence factors TSST-1 and ETA were present only
in a few MRSA isolates. However, patients who were
infected by pulsotype C isolates with the ETA gene all
underwent amputation (Table 3). Unlike the Hlg genes,
which were present in all isolates, the ETB gene was
absent from all isolates. Other series has also reported a
lower frequency of toxin genes carriage. Miller reported
that no TSST-1, ETA and ETB genes were identified in
any of the CA-MRSA strains [4]. The severity of PVL-
specific pathology remains controversial. The PVL genes
have been detected in approximately 50% of S. aureus
isolates that are responsible for subcutaneous abscesses
and cellulitis, but not in isolates that are associated with
deep-seated infections [36]. A study of isogenic PVL
strains of pulsotypes USA300 and USA400 also found
that PVL was not the major virulence factor for necrotiz-
ing fasciitis [37]. Conversely, the PVL gene has been
detected in five NF-associated ST8/pulsotype USA 300/
SCCmec IV CA-MRSA isolates [4]. A recent investigation
stated that PVL tends to damage the muscle rather than
skin in young mice [38]. These results are consistent with
the clinical characteristics of necrotizing fasciitis, which
typically damages deep tissues but may spare skin.
Thromboangiitis obliterans followed by the occlusion of
cutaneous perforators may be the leading cause of NF
cases with extensive skin necrosis - rather than direct
cutaneous invasion.
In Taiwan, ST239/pulsotype A type is the most preva-
lent clone of HA-MRSA and the ST59/pulsotype C and D
isolates are the dominant clones of CA-MRSA [30,39-41].
Moreover, SCCmec VII and multi-drug resistant CA-
MRSA isolates have been identified in pediatric patients
with skin and soft tissue infections in northern Taiwan
[29]. This investigation identified various NF-associated
MRSA strains, which have been the prevalent clones in
Taiwan. These strains differ distinctly from the particular
ST8/pulsotype USA300 CA-MRSA clone, which has been
identified as a dominant cause of necrotizing fasciitis in
the USA [4,6]. The results herein verified that the SCCmec
M  19  31 151 M  49  52 104 46  M 215 100 123 156 M 151 165  10  93 141 M 
P u l s o t y p e     A               C                 D             A   O    C   N D 1   N D 2  
Figure 2 PFGE patterns of SmaI-digested genomic DNA of MRSA isolates collected from the patients with necrotizing fasciitis.M :
lambda DNA. ND1 and ND2 mean new pulsotypes.
Changchien et al. BMC Infectious Diseases 2011, 11:297
http://www.biomedcentral.com/1471-2334/11/297
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element was present in both CA- and HA-MRSA isolates
with ST59/pulsotype C and pulsotype D (Table 3), sug-
gesting transmission of the community strain of MRSA
into the hospital setting, and that the community strain
had became a hospital-associated pathogen in Taiwan [9].
E m p i r i ca n t i b i o t i ct h e r a p yf o rN Fp a t i e n t sm u s tb em o d i -
fied for the broad coverage of the regional MRSA strains.
Earlier, antimicrobial susceptibility patterns could be used
to differentiate CA-MRSA from HA-MRSA isolates; how-
ever, this approach is no longer reliable because CA-MRSA
may also develop resistance to non-b-lactam antibiotics
[34]. Clindamycin has been a common prescribed medica-
tion for MRSA infection. In this investigation, both CA-
and HA-MRSA isolates exhibited extremely high resistance
(>90%) to erythromycin and clindamycin (Table 1), which
were contradicting findings obtained from different coun-
tries, but supporting other findings from Taiwan [5,7,42].
Trimethoprim-sulfamethoxazole was the only drug asso-
ciated with different susceptibility between CA- and
HA-MRSA strains, to which CA-MRSA isolates were sig-
nificantly more susceptible than HA-MRSA isolates [9].
For complex skin and soft tissue infections associated with
considerable comorbidities, treatment with appropriate
antimicrobials is required to reduce clinical failures.
Delayed treatments are associated with the morbidity and
mortality of MRSA infection [43]. The most common anti-
biotic prescribing error in this investigation was inadequate
coverage of the pathogen MRSA. Even though vancomycin
was administered to 46.9% of MRSA patients after the
susceptibility test, 83.7% of the patients with MRSA infec-
tions herein underwent empiric therapy with antibiotics
that were not active against the MRSA strains at the
time of hospital admission. This fact may explain the
higher amputation and reconstruction rates of patients
who were infected by MRSA than those of patients who
were infected by MSSA or non-S. aureus. An effective
empiric antimicrobial therapy may be critical to ensure a
favorable surgical outcome for NF patients with MRSA
infection. The empiric use of vancomycin should be con-
sidered for NF patients based on epidemiologic data and
nature of patient’s exposure in an area where high preva-
lence of methicillin resistance was noted such as Taiwan.
Additionally, to prevent the emergence of the resistant
strains and prolong the effectiveness of currently available
antimicrobials, empiric therapy using agents such as van-
comycin should not be prescribed for immuno-competent
patients with mild skin and soft-tissue infections [44].
Conclusion
MRSA has emerged as an important cause of necrotizing
fasciitis in Taiwan. In this investigation, the prevalence of
MRSA in 247 NF cases over a four-year period was
19.8%. NF patients with MRSA infection presented more
severe clinical outcomes in terms of amputation rate and
reconstruction rate than those with MSSA or non-S. aur-
eus infection. In contrast to CA-MRSA infection, NF
patients with HA-MRSA infection had a significantly
higher amputation rate, comorbidity, C-reactive protein
level, and involvement of lower extremity. Further, HA-
MRSA isolates were more resistant to trimethoprim-sul-
famethoxazole. The ST239/pulsotype A, ST59/pulsotype
C and D MRSA are the major pathogenic clones to cause
necrotizing fasciitis. The ST59/pulsotype D/SCCmec V/
PVL MRSA isolates were found in both CA- and HA-
MRSA; the ETA gene was found in ST59/pulsotype C/
SCCmec type IV CA- and HA-MRSA. As well as surgical
debridement, initial empiric antimicrobials with a broad
coverage for MRSA should be considered in the treat-
ment of NF patients in an endemic area.
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